Edition:
United States

PRA Health Sciences Inc (PRAH.OQ)

PRAH.OQ on NASDAQ Stock Exchange Global Select Market

85.16USD
11:06am EST
Change (% chg)

$-3.83 (-4.30%)
Prev Close
$88.99
Open
$88.50
Day's High
$88.50
Day's Low
$85.16
Volume
77,716
Avg. Vol
162,016
52-wk High
$95.47
52-wk Low
$57.73

Latest Key Developments (Source: Significant Developments)

PRA Health Sciences Reports Q4 Loss Per Share $0.25
Wednesday, 21 Feb 2018 04:00pm EST 

Feb 21 (Reuters) - PRA Health Sciences Inc ::PRA HEALTH SCIENCES, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES Q1 AND FY 2018 GUIDANCE.Q4 ADJUSTED EARNINGS PER SHARE $1.04.Q4 GAAP LOSS PER SHARE $0.25.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.00 TO $4.15.SEES FY 2018 GAAP EARNINGS PER SHARE $2.80 TO $2.95.SEES FY 2018 REVENUE $2.84 BILLION TO $2.95 BILLION.FY2018 EARNINGS PER SHARE VIEW $4.06 -- THOMSON REUTERS I/B/E/S.‍DURING THREE MONTHS ENDED DECEMBER 31, 2017, COMPANY RECOGNIZED TRANSACTION-RELATED COSTS OF $75.9 MILLION​.FY2018 REVENUE VIEW $2.32 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $655.9 MILLION VERSUS $472.4 MILLION.Q4 EARNINGS PER SHARE VIEW $1.02 -- THOMSON REUTERS I/B/E/S.  Full Article

PRA Health Sciences Says Unit Entered First Amendment, Second Joinder Agreement To Credit Agreement
Friday, 29 Dec 2017 05:18pm EST 

Dec 29 (Reuters) - Pra Health Sciences Inc ::PRA HEALTH SCIENCES SAYS ON DEC 28, UNIT ENTERED FIRST AMENDMENT, SECOND JOINDER AGREEMENT TO CREDIT AGREEMENT DATED DEC 6, 2016‍​ - SEC FILING.PRA HEALTH SCIENCES - PURSUANT TO AMENDMENT, CREDIT AGREEMENT AMENDED TO PROVIDE NEW TRANCHE OF TERM LOANS IN AGGREGATE PRINCIPAL AMOUNT OF $601.6 MILLION.PRA HEALTH SCIENCES INC - ‍PURSUANT TO AMENDMENT, PRA RECEIVED NEW REVOLVING CREDIT COMMITMENTS IN AGGREGATE PRINCIPAL AMOUNT OF $10O MILLION.  Full Article

PRA Health Sciences reports Q3 adjusted earnings per share $0.88
Wednesday, 25 Oct 2017 04:00pm EDT 

Oct 25 (Reuters) - PRA Health Sciences Inc :PRA Health Sciences, Inc reports third quarter 2017 results and updates full year 2017 guidance.Q3 adjusted earnings per share $0.88.Q3 GAAP earnings per share $0.73.Q3 earnings per share view $0.85 -- Thomson Reuters I/B/E/S.PRA Health Sciences Inc says ‍updating full year 2017 service revenue guidance to between $1.914 billion and $1.926 billion​.PRA Health Sciences Inc sees ‍full year 2017 GAAP net income per diluted share to between $2.31 and $2.38​.PRA Health Sciences Inc sees ‍full year 2017 adjusted net income per diluted share to between $3.28 and $3.35​.FY2017 earnings per share view $3.20, revenue view $1.91 billion -- Thomson Reuters I/B/E/S.PRA Health Sciences Inc qtrly ‍total revenue $582 million versus $453.3 million.  Full Article

PRA Health Sciences prices secondary offering of 10 mln shares
Wednesday, 9 Aug 2017 06:45am EDT 

Aug 9 (Reuters) - PRA Health Sciences Inc :PRA Health Sciences Inc announces pricing of secondary offering of 10,000,000 shares of common stock.PRA Health Sciences - ‍shares will be offered from time to time at prices related to prevailing market prices or at negotiated prices​.  Full Article

PRA Health Sciences says selling stockholders are offering 10 mln shares of co's stock
Wednesday, 9 Aug 2017 06:26am EDT 

Aug 9 (Reuters) - PRA Health Sciences Inc :PRA Health Sciences files to say selling stockholders are offering 10 million shares of co's common stock - SEC filing.PRA Health Sciences says it will not receive any proceeds from sale of co's common stock by the selling stockholders.  Full Article

PRA Health Sciences says secondary offering of 10 mln shares of common stock
Tuesday, 8 Aug 2017 04:43pm EDT 

Aug 8 (Reuters) - PRA Health Sciences Inc :Pra health sciences, inc. Announces secondary offering of 10,000,000 shares of common stock.  Full Article

PRA Health Sciences Q2 adjusted earnings per share $0.79
Monday, 7 Aug 2017 04:16pm EDT 

Aug 7 (Reuters) - PRA Health Sciences Inc :Pra health sciences, inc. Reports second quarter 2017 results and updates full year 2017 guidance.Q2 adjusted earnings per share $0.79.Q2 gaap earnings per share $0.45.Q2 earnings per share view $0.74 -- Thomson Reuters I/B/E/S.Pra health sciences inc - ‍updating its full year 2017 service revenue guidance to between $1.825 billion and $1.855 billion​.Pra health sciences inc - sees ‍fy gaap net income per diluted share to between $2.17 and $2.26​.Pra health sciences inc - sees ‍fy adjusted net income per diluted share to between $3.11 and $3.20​.Fy2017 earnings per share view $3.15, revenue view $1.82 billion -- Thomson Reuters I/B/E/S.Pra health sciences inc - ‍for three months ended june 30, 2017, service revenue was $457.9 million, which represents growth of 16.2%​.  Full Article

PRA Health Sciences to acquire Symphony Health Solutions
Monday, 7 Aug 2017 04:15pm EDT 

Aug 7 (Reuters) - Pra Health Sciences Inc :Pra health sciences to acquire symphony health solutions, a leading provider of integrated health data and analytics delivered as cloud-based solutions.Pra health sciences inc - ‍enters into definitive agreement to acquire symphony health solutions for upfront cash payment of $ 530 million​.Pra health sciences inc - ‍transaction expected to be immediately accretive to pra health sciences' adjusted net income per diluted share​.Says ‍symphony health is expected to generate revenues in excess of $200 million in calendar year 2017​.Pra health sciences - entered debt financing commitments with pnc bank for amounts that are sufficient to provide funds necessary to consummate deal.  Full Article

PRA Health Sciences and Jumo announce partnership
Monday, 19 Jun 2017 10:00am EDT 

June 19 (Reuters) - PRA Health Sciences Inc :PRA Health Sciences and Jumo announce partnership.  Full Article

Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083
Thursday, 11 May 2017 08:30am EDT 

May 11 (Reuters) - Delmar Pharmaceuticals Inc : :Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 in recurrent glioblastoma multiforme (gbm).Delmar Pharmaceuticals- have resources to initiate phase 3 study of val-083 as single agent treatment for gbm patients who failed both temozolomide & bevacizumab.  Full Article

BRIEF-PRA Health Sciences Reports Q4 Loss Per Share $0.25

* PRA HEALTH SCIENCES, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES Q1 AND FY 2018 GUIDANCE